Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Stockholders Deficit

v3.20.4
Consolidated Statements of Stockholders Deficit - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Noncontrolling Interest [Member]
Series B Preferred Stock [Member]
Total
Balance at Dec. 31, 2018 $ 15 $ 230,754 $ (219,461) $ (2,909) $ 5,760 $ 14,159
Balance (in shares) at Dec. 31, 2018 15,482,083       9,161  
Stock-based compensation $ 0 340 0 0 $ 0 340
Series A Preferred Stock Dividends 0 0 (248) 0 0 (248)
Issuance of SYN Biomics Stock $ 0 (36) 0 108 $ 0 72
Conversion of Series B Preferred Stock to Common (in shares) 1,324,347       (1,523)  
Conversion of Series B Preferred Stock to Common $ 2 1,522 (525) 0 $ (999) 0
Net loss 0 0 (15,303) 0 0 (15,303)
Non-controlling interest 0 0 0 (77) 0 (77)
Balance at Dec. 31, 2019 $ 17 232,580 (235,537) (2,878) $ 4,761 (1,057)
Balance (in shares) at Dec. 31, 2019 16,806,430       7,638  
Stock-based compensation $ 0 350 0 0 $ 0 350
Stock issued under "at-the-market" offering $ 9 3,350 0 0 0 3,359
Stock issued under "at-the-market" offering (in shares) 9,256,535          
Series A Preferred Stock Dividends $ 0 0 (254) 0 0 (254)
Issuance of SYN Biomics Stock 0 0 0 178 0 178
Effect of Warrant exercise price adjustment $ 0 880 (880) 0 $ 0 0
Conversion of Series B Preferred Stock to Common (in shares) 3,186,960       (3,665)  
Conversion of Series B Preferred Stock to Common $ 3 3,661 (1,380) 0 $ (2,284) 0
Net loss 0 0 (10,043) 0 0 (10,043)
Non-controlling interest 0 0 0 (73) 0 (73)
Balance at Dec. 31, 2020 $ 29 $ 240,821 $ (248,094) $ (2,773) $ 2,477 $ (7,540)
Balance (in shares) at Dec. 31, 2020 29,249,925       3,973